| Literature DB >> 28153089 |
Rachid El Fatimy1, Shruthi Subramanian1, Erik J Uhlmann1, Anna M Krichevsky2.
Abstract
Glioblastoma (GBM) brain tumor remains among the most lethal and incurable human diseases. Oncogenic microRNA-10b (miR-10b) is strongly and universally upregulated in GBM, and its inhibition by antisense oligonucleotides (ASOs) reduces the growth of heterogeneous glioma cells; therefore, miR-10b represents a unique therapeutic target for GBM. Here we explored the effects of miR-10b gene editing on GBM. Using the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system, we investigated effects of miR-10b gene editing on the growth of cultured human glioma cells, tumor-initiating stem-like cells, and mouse GBM xenografts, as well as the oncogene-induced transformation of normal astrocytes. We show that GBM is strictly "addicted" to miR-10b and that miR-10b gene ablation is lethal for glioma cell cultures and established intracranial tumors. miR-10b loss-of-function mutations lead to the death of glioma, but not other cancer cell lines. We have not detected escaped proliferative clones of GBM cells edited in the miR-10b locus. Finally, neoplastic transformation of normal astrocytes was abolished by the miR-10b-editing vectors. This study demonstrates the feasibility of gene editing for brain tumors in vivo and suggests virus-mediated miR-10b gene ablation as a promising therapeutic approach that permanently eliminates the key regulator essential for tumor growth and survival.Entities:
Keywords: CRISPR-Cas9; brain tumor; cancer; gene editing; genome editing; glioblastoma; microRNA-10b; ncRNA; orthotopic animal models; therapy
Mesh:
Substances:
Year: 2017 PMID: 28153089 PMCID: PMC5368404 DOI: 10.1016/j.ymthe.2016.11.004
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454